WHAT IS A NORMAL CA125 LEVEL

被引:59
作者
ALAGOZ, T [1 ]
BULLER, RE [1 ]
BERMAN, M [1 ]
ANDERSON, B [1 ]
MANETTA, A [1 ]
DISAIA, P [1 ]
机构
[1] UNIV CALIF IRVINE,IRVINE MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,ORANGE,CA 92668
关键词
D O I
10.1006/gyno.1994.1093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CA125 is a coelomic epithelial antigen which is widely used to monitor residual disease in patients undergoing chemotherapy for ovarian cancer. Interpretation of serum CA125 levels has been based on a normal value of 35 U/ml which was derived by screening a young, general population of blood donors which included women with intact reproductive systems. This study addresses the issue of what constitutes a normal serum CA125 level following successful surgical therapy for gynecologic malignancy. Three hundred ninety-three CA125 values were measured in 145 patients after an elapsed time of at least 1 year following completion of surgical therapy for early-stage endometrial or cervical adenocarcinoma. All patients were without evidence of recurrent disease. The mean duration of follow-up was 4.3 years with a median of 3.7 years. Sixty-seven percent of the CA125 values were less than 10 U/ml; 95% were less than or equal to 20 U/ml. The median value for this patient population was 7.5 U/ml with a mode of 7.1 U/ml. There was no correlation between patient age and CA125 levels. These data suggest that the normal value for CA125 used for patient follow-up after treatment for gynecologic adenocarcinoma needs to be redefined. Our data support an upper limit of normal of 20 U/ml and encourage further study on the clinical impact of this new definition. (C) 1994 Academic Press, Inc.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 19 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]   CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS [J].
BEREK, JS ;
KNAPP, RC ;
MALKASIAN, GD ;
LAVIN, PT ;
WHITNEY, C ;
NILOFF, JM ;
BAST, RC .
OBSTETRICS AND GYNECOLOGY, 1986, 67 (05) :685-689
[4]   SERUM CA125 REGRESSION IN EPITHELIAL OVARIAN-CANCER - CORRELATION WITH REASSESSMENT FINDINGS AND SURVIVAL [J].
BULLER, RE ;
BERMAN, ML ;
BLOSS, JD ;
MANETTA, A ;
DISAIA, PJ .
GYNECOLOGIC ONCOLOGY, 1992, 47 (01) :87-92
[5]   OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER [J].
CANNEY, PA ;
MOORE, M ;
WILKINSON, PM ;
JAMES, RD .
BRITISH JOURNAL OF CANCER, 1984, 50 (06) :765-769
[6]   CA-125 - A USEFUL MARKER IN ENDOMETRIAL CARCINOMA [J].
DUK, JM ;
AALDERS, JG ;
FLEUREN, GJ ;
DEBRUIJN, HWA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (05) :1097-1102
[7]  
DUK JM, 1989, OBSTET GYNECOL, V73, P661
[8]   THE PROGNOSTIC IMPLICATIONS OF LOW SERUM CA-125 LEVELS PRIOR TO THE 2ND-LOOK OPERATION FOR STAGE-III AND STAGE-IV EPITHELIAL OVARIAN-CANCER [J].
GALLION, HH ;
HUNTER, JE ;
VANNAGELL, JR ;
AVERETTE, HE ;
CAIN, JM ;
COPELAND, LJ ;
HIGGINS, RV ;
HUSSEINZADEH, N ;
NAHHAS, WA ;
PARTRIDGE, EE ;
PURSELL, SH .
GYNECOLOGIC ONCOLOGY, 1992, 46 (01) :29-32
[9]  
KIVINEN S, 1986, OBSTET GYNECOL, V67, P468
[10]  
KLUG TL, 1984, CANCER RES, V44, P1048